William J. Febbo - 02 Oct 2024 Form 4 Insider Report for Augmedix, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 02 Oct 2024
Net transaction value: -$382,070
SEC form: 4
Accepted by SEC: 04 Oct 2024, 13:17:00 UTC
Prior SEC filing: 15 Jul 2024
Next SEC filing: 16 Dec 2024
Source filing: View source filing
Reporting owner signature: /s/ Todd Holvick, Attorney-in-Fact

Key filing fact

William J. Febbo filed Form 4 for Augmedix, Inc. on 04 Oct 2024.

Key facts

This page summarizes William J. Febbo's Form 4 filing for Augmedix, Inc..
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 04 Oct 2024, 13:17.

Change

Previous filing in this sequence was filed on 15 Jul 2024.
Current net transaction value: -$382,070.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUGX transaction

Common Stock

Disposed to Issuer

Transaction value: $382,070
Shares: -162,583
Change %: -100%
Price: $2.35
Shares after: 0
Date: 02 Oct 2024
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AUGX transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value: $0
Shares: -50,000
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 02 Oct 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $2.80
Footnotes: F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

William J. Febbo is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

Disposed of in connection with the merger of Augmedix, Inc. ("Augmedix") with and into Anderson Merger Sub, Inc. (the "Merger Sub"), effective October 2, 2024 (the "Merger"), pursuant to the Agreement and Plan of Merger dated as of July 19, 2024, among Augmedix, Commure, Inc., and Merger Sub (the "Merger Agreement"). In connection with the Merger, the shares listed were canceled and converted into the right to receive $2.35 per share, without interest (the "Merger Consideration"), and subject to applicable tax withholdings.

Footnote F2

Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each stock option (the "Company Option") that was outstanding, unexercised and vested as of immediately prior to the Effective Time with a per share exercise price ("Per Share Exercise Price") that was less than the Merger Consideration, was cancelled and converted into the right to receive an amount in cash (without interest and less any applicable withholding taxes) equal to the product of (i) the aggregate number of shares of common stock of Augmedix (the "Company Common Stock") underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the Per Share Exercise Price of such Company Option. Each Company Option that had a Per Share Exercise Price that was equal to or exceeded the amount of the Merger Consideration at the Effective Time was cancelled for no consideration.

Footnote F3

Each Company Option that was unvested and had a Per Share Exercise Price that was less than the amount of the Merger Consideration at the Effective Time was replaced with a cash incentive program, which in either case preserves the compensation elements and vesting terms of the Company Option.

Footnote F4

The option is granted under the Augmedix 2020 Equity Incentive Plan. The option will vest monthly in equal increments for one (1) year starting on March 28, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date, and will be fully vested on March 28, 2023.